Food and drug companies have expressed optimism, but the new health secretary and his MAHA movement will likely make waves.

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the stock market and healthcare system. Shares have performed well in 2025 ...

and Zepbound (for weight loss). Together, those two products generated $5.4 billion in sales for Eli Lilly last quarter, or 40% of the top line. Demand has been so strong that shortages of Lilly's ...

A groundbreaking study shows how Zepbound, a popular weight loss medication, could become a key treatment for heart failure ...

For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative. The stock is reasonably valued given the growth opportunities in front ...

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate ...

After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE ... while revenue for Zepbound surged from $175.8 million to $1.9 billion.

A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...

The new weight loss drug offers promising results for those who are overweight or obese. Learn about how Zepbound works, its ...